Chimeric Antigen Receptor T-cell (CAR T-cell) Therapy

The Can­cer Statewide Clin­i­cal Net­work have led col­lab­o­ra­tions with a mul­ti­dis­ci­pli­nary group of clin­i­cians and researchers across all local health net­works to out­line what is need­ed to facil­i­tate the deliv­ery of CAR T‑cells in South Aus­tralia. A project has been ini­ti­at­ed to inves­ti­gate and for­mu­late strate­gies to estab­lish a CAR T‑cell ther­a­py ser­vice in South Australia.

Chimeric Anti­gen Recep­tor T‑cell (CAR T‑cell) Ther­a­py is an evi­dence-based, inter­na­tion­al­ly recog­nised ther­a­py endorsed by Can­cer Aus­tralia and the Aus­tralian Gov­ern­ment Med­ical Spe­cial­ist Advi­so­ry Com­mit­tee (MSAC) which can improve chance of cure for cer­tain types of leukaemia and lym­phoma. The estab­lish­ment of a South Aus­tralian ser­vice would allow patients to access this care clos­er to home there­by improv­ing their qual­i­ty of life. It would also enhance equi­ty of access for those who may be unable to trav­el inter­state to receive this treatment.

What is CAR T‑cell ther­a­py? An intro­duc­tion to CAR T‑cell ther­a­py video has been pub­lished by NSW Health Immune Effec­tor Cell Ser­vice which was in part­ner­ship with the NSW Agency for Clin­i­cal Innovation.

For more infor­ma­tion, vis­it the Agency for Clin­i­cal Infor­ma­tion web­site.